期刊文献+

经沉默免疫负调控基因技术处理的树突状细胞联同细胞毒性T淋巴细胞对HepG2细胞移植瘤的抑制作用 被引量:4

Inhibitory effect of iAPA- DC /CTL on HepG2 xenograft in nude mice
下载PDF
导出
摘要 目的观察经沉默免疫负调控基因(iAPA)技术处理的树突状细胞(DC)联同细胞毒性T淋巴细胞(CTL)(iAPA-DC/CTL)对HepG2细胞移植瘤的抑制作用。方法利用人肝癌细胞系HepG2建立裸鼠皮下移植瘤模型,将12只裸鼠随机分为2组:生理盐水对照组(C组)和iAPA-DC/CTL组(DC组),每组6只,行iAPA-DC/CTL治疗4次(1周/次)后处死。实验期间观察各组裸鼠的肿瘤生长,测量肿瘤长短径并描绘肿瘤生长曲线,称量瘤重并计算抑瘤率,病理检测。两组间均数比较采用成组t检验。结果造模成功率为92.31%。C组和DC组肿瘤体积分别为:(697.69±143.99)、(485.64±188.75)mm3,DC组生长相对缓慢(t=2.28,P<0.05);C组和DC组肿瘤重量分别为:(0.32±0.07)、(0.22±0.08)g,DC组肿瘤重量小于对照组(t=2.31,P<0.05),抑瘤率为30.39%。肿瘤免疫组化染色后T淋巴细胞计数分别为:C组未见、DC组(39.74±5.11)个/高倍视野,DC组肿瘤内T细胞数多于对照组(t=19.05,P<0.05)。结论 iAPA-DC/CTL能够有效抑制HepG2细胞裸鼠皮下移植瘤的生长。 Objective To investigate the inhibitory effect of inhibition of antigen presentation attenuators( iAPA)- based dendritic cells( DC) and cytotoxic T lymphocytes( CTL)( iAPA- DC/CTL) on HepG2 xenograft in nude mice. Methods Human hepatocarcinoma HepG2 cells were subcutaneously implanted into nude mice on nude mice to establish a HepG2 xenograft model transplanted tumor model of human HCC. Twelve nude mice were randomly and equally divided into two groups: normal saline control group( C group) and iAPA- DC /CTL group( DC group). After four times of treatment with iAPA- DC /CTL( once a week),all mice were sacrificed. Tumor growth was evaluated by measuring the long and short diameters and delineating the tumor growth curve. The tumors were weighed,and the tumor inhibition rate was calculated. In addition,histopathological examination was performed. Comparison of means between the two groups was made by independent- samples t test. Results The HepG2 xenograft model was successfully established in 92. 31% of all mice. The tumor volume was 697. 69 ± 143. 99 mm3 in C group and 485. 64 ± 188. 75 mm3 in DC group; the tumor growth was significantly slower in DC group than in C group( t = 2. 28,P〈0. 05). The tumor weight was 0. 32 ± 0. 07 g in C group and 0. 22 ± 0. 08 g in DC group; DC group had a significantly lower tumor weight than C group( t = 2. 31,P〈0. 05),and the tumor inhibition rate was 30. 39%. After immunohistochemical staining,T lymphocyte count was 0 cell /high- power field( HPF) in C group and 39. 74 ± 5. 11 cells /HPF in DC group; the number of T lymphocytes in DC group was significantly higher than that in C group( t = 19. 05,P〈0. 05). Conclusion iAPA- DC /CTL can effectively inhibit the growth of subcutaneous HepG2 xenograft in nude mice.
出处 《临床肝胆病杂志》 CAS 2014年第9期891-894,共4页 Journal of Clinical Hepatology
关键词 肝肿瘤 实验性 基因表达调控 树突细胞 T淋巴细胞 细胞毒性 liver neoplasms experimental gene expression regulation dendritic cells T-lymphocytes cytotoxic
  • 相关文献

参考文献12

  • 1李焱,程朋.中晚期肝癌临床治疗进展[J].临床肝胆病杂志,2014,30(3):233-236. 被引量:54
  • 2SHEN L, EVEL-KABLER K, STRUBE R, et al. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen - specific anti - tumor immunity[ J ]. Nat Biotechnol, 2004, 22 ( 12 ) : 1546 - 1553.
  • 3HONG B, REN W, SONG XT, et al. Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte - derived dendritic cells [ J ]. Cancer Res, 2009, 69(20): 8076 -8084.
  • 4UDAGAWA M, KUDO -SAITO C, HASEGAWA G, et al. En- hancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination withcryoabla- tive tumor pretreatment and Bacillus Calmette - Guerin cell wall skeleton stimulation[J]. Clin Cancer Res, 2006, 12 (24):7465 -7475.
  • 5刘业六,钱海鑫,张逖,庞利群,唐晓军,刘卫东,张娟.趋化因子受体-6小干扰RNA对人肝癌HCCLM6细胞裸鼠皮下移植瘤的抑制作用[J].中华实验外科杂志,2013,30(12):2577-2579. 被引量:5
  • 6林贤凡,吴金明,林春景,金思思.HBV S-ecdCD40L融合基因修饰对树突状细胞功能的影响[J].医学研究杂志,2013,42(12):49-53. 被引量:2
  • 7程婷婷,徐希,葛杭萍,陈枫煜,梁彬,俞康.慢病毒介导的自杀基因对树突状细胞的杀伤作用[J].医学研究杂志,2014,43(4):71-75. 被引量:2
  • 8CURIEL T J, COUKOS G, ZOU L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[ J]. Nat Med, 2004, 10(9) : 942 -949.
  • 9PALUCKAL AK, UENO H, FAY J, et al. Dendritic cells: a critical player in cancer therapy? [ J ]. J Immunother, 2008, 31 (9) : 793 -805.
  • 10PARK HY, JIN JO, SONG MG, et al. Expression of dendritic cell markers on cultured neutrophils and its modulation by an- ti -apoptotic and pro - apoptotic compounds [ J ]. Exp Mol Med, 2007, 39(4): 439 -449.

二级参考文献32

  • 1Gerhild Becker,Tarik Soezgen,Manfred Olschewski,Joerg Laubenberger,Hubert Erich Blum,Hans-Peter Allgaier.Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma[J].World Journal of Gastroenterology,2005,11(39):6104-6109. 被引量:32
  • 2周光炎.免疫学原理[M].上海:上海科学技术出版社,2010:86-89.
  • 3Li Y,Tian B, Yang J, et al. Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials estab- lished through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol,2004,130:460-468.
  • 4Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta, 2009,1796:293-308.
  • 5Murphy PM. Chemokines and the molecular basis of cancer metasta- sis. N Engl J Med, 2001,345 : 833-835.
  • 6MUller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature,2001,410:50-56.
  • 7Stelljies M,Beelen DW,Braess J,et al.Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia:land-mark analysis from a single prospective multicenter trial[J].Haematologica,2011,96 (7):972-979.
  • 8Pavlu J,Szydlo RM,Goldman JM,et al.Three decades of transplantation for chronic myeloid leukemia:what have we learned?[J].Blood,2011,117 (3):755-763.
  • 9Stenger EO,Turnguist HR,Mapara MY,et al.Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity[J].Blood,2012,119(22):5088-5103.
  • 10Nienhuis AW.Development of gene therapy for blood disorders:an update[J].Blood,2013,122(9):1556-1564.

共引文献58

同被引文献27

  • 1杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1479
  • 2范文哲,翁慧雯,姚学华,张应强,王于.经肝动脉栓塞化疗联合^(125)I粒子治疗肝细胞癌的Meta分析[J].消化肿瘤杂志(电子版),2013,5(2):114-118. 被引量:3
  • 3王金湖,邵启祥,阴晴,王胜军,潘湘涛,顾超,许化溪.人PBMC和脐血CD34^+细胞诱导DC2的实验方法研究[J].中国交通医学杂志,2006,20(2):167-170. 被引量:1
  • 4Zheng Zhang~1 Fu-Sheng Wang~(1,2) ~1Research Center of Biological Therapy,Beijing 302 Hospital,Beijing 100039,China,~2Research Centre of Biological Therapy,Beijing Institute of Infectious Diseases,Beijing 302 Hospital,100 Xi Si Huan Middle Road,Beijing 100039,China..Plasmacytoid Dendritic Cells Act as the Most Competent Cell Type in Linking Antiviral Innate and Adaptive Immune Responses[J].Cellular & Molecular Immunology,2005,2(6):411-417. 被引量:16
  • 5Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease [J]. Nature, 2007, 448 (7152): 427-434.
  • 6Leung RK, Whittaker PA. RNA interference: From gene silencing to gene-speeific therapeutics [J]. Pharmacol Ther, 2005, 107 (2): 222-239.
  • 7Zhang B, Wu T, Chen M, et al. The CD40/CD40L system: a new therapeutic target for disease [J]. Immunol Lett, 2013, 153 (1/2): 58-61.
  • 8Danese S, Scaldaferri F, Vetrano S, et al. Critical role of the CD40-CD40-1igand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease [J]. Gut, 2007, 56 (9): 1248-1256.
  • 9LI ZY, Mao H, Kallick DA, et al. The effects of thiophosphate substitutions on native siRNA gene silencing [J]. Biochem Bioph Res Commun, 2005, 329 (3): 1026-1030.
  • 10Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease [ J ]. J Pharmacol Toxicol Methods, 2004, 50 (2): 81-92.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部